Xeris Pharmaceuticals ((XERS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Xeris Pharmaceuticals recently completed a Phase 2 study titled ‘A Phase 2, Multicenter, Non-Randomized, Open-Label, Single Arm, Self-controlled Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism.’ The study aimed to establish a dose conversion factor from oral levothyroxine to XP-8121, a subcutaneous injection, and evaluate its safety and tolerability in hypothyroidism patients.
Intervention/Treatment: The study tested XP-8121, a subcutaneous injection of levothyroxine sodium, intended to replace oral levothyroxine in hypothyroidism treatment, offering a potentially more convenient dosing schedule.
Study Design: This non-randomized, open-label study utilized a single-group intervention model without masking. Its primary purpose was treatment, focusing on dose conversion and safety assessment.
Study Timeline: The study began on May 15, 2023, and was completed with results submitted by June 4, 2025. The last update was recorded on July 2, 2025, marking significant milestones in the study’s progression.
Market Implications: The completion of this study could positively influence Xeris Pharmaceuticals’ stock performance by showcasing their commitment to innovative treatment options. This development may also impact investor sentiment, especially as the company competes in the hypothyroidism treatment market.
The study is now completed, with further details available on the ClinicalTrials portal.